Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
Be 'active' in the market while NOT being tied to your desk.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| MRNA | Moderna, Inc. | -2.31% | 324.21 | 0.0% | $4670.09m | |
| BNTX | BioNTech SE | -1.06% | 247.68 | 0.0% | $730.32m | |
| NVAX | Novavax, Inc. | -4.59% | 161.95 | 79.4% | $715.24m | |
| AMGN | Amgen, Inc. | 0.51% | 207.84 | 1.4% | $575.65m | |
| SNSS | Sunesis Pharmaceuticals, Inc. | -7.57% | 6.47 | 0.7% | $452.28m | |
| GILD | Gilead Sciences, Inc. | -0.76% | 67.63 | 1.0% | $426.45m | |
| REGN | Regeneron Pharmaceuticals, Inc. | -0.43% | 553.24 | 2.7% | $408.99m | |
| ILMN | Illumina, Inc. | 0.45% | 409.93 | 3.3% | $392.87m | |
| CCXI | ChemoCentryx, Inc. | -7.04% | 34.47 | 2.9% | $387.64m | |
| XLRN | Acceleron Pharma, Inc. | 0.50% | 172.94 | 5.3% | $345.45m | |
| VRTX | Vertex Pharmaceuticals, Inc. | -0.07% | 181.77 | 1.9% | $259.59m | |
| BIIB | Biogen, Inc. | -1.43% | 281.19 | 1.7% | $243.39m | |
| OCGN | Ocugen, Inc. | -13.83% | 8.66 | 0.0% | $178.37m | |
| XENE | Xenon Pharmaceuticals, Inc. | 2.12% | 33.66 | 0.4% | $178.19m | |
| JSPR | Jasper Therapeutics, Inc. | 31.57% | 16.42 | 0.0% | $158.53m |
Company Profile
Bio-Techne Corp. engages in the development, manufacture and sale of biotechnology reagents and instruments for the research and clinical diagnostic markets. It operates through the following segments: Protein Sciences and Diagnostics &Genomics. The Protein Sciences segment develops and manufactures purified proteins and reagent solutions most notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. This segment also includes protein analysis solutions that offer researchers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. The Diagnostics &Genomics segment develops and manufactures diagnostic products, including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays, including the ExoDx Prostate(IntelliScore) test (EPI) for prostate cancer diagnosis. This segment also manufactures and sells advanced tissue-based in-situ hybridization assays (ISH) for research and clinical use. The company was founded in 1976 and is headquartered in Minneapolis, MN.